Top View
- CDR Pharmacoeconomic Review Report for Trelegy Ellipta
- A Study with Cumulative Doses of Formoterol and Salbutamol in Children with Asthma
- Long-Acting Beta-Agonist
- Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol
- Safety of Formoterol by Turbuhaler® As Reliever Medication Compared With
- Attachment: Product Information: Indacaterol Maleate/ Glycopyrronium Bromide
- Efficacy of a New Once-Daily Long-Acting Inhaled B2-Agonist Indacaterol Versus Twice-Daily Formoterol in COPD
- Chronic Obstructive Pulmonary Disease: Indacaterol/Glycopyrronium (Ultibro Breezhaler)
- TRELEGY ELLIPTA (Fluticasone Furoate, Umeclidinium, and Vilanterol Changes Occur, Consider Appropriate Therapy
- Formoterol and Salbutamolinhibit Bradykinin- and Histamine-Induced
- Duaklir Genuair INN-Aclidinium Bromide/Formoterol Fumarate
- Revised Clinical Study Protocol Drug Substance Budesonide/Formoterol Study Code D589SC00003 Edition Number 4 Date 12 October 2016
- Formoterol Fumarate Dihydrate
- Inhalation Composition Containing Aclidinium for Treatment of Asthma and Chronic Obstructive Pulmonary Disease
- Product Information
- Trelegy Ellipta (Fluticasone Furoate/Umeclidinium/Vilanterol)
- Anticachectic Effects of Formoterol: a Drug for Potential Treatment of Muscle Wasting
- The Musclehypertrophic Effect of Clenbuterol Is Additive to The
- A Twice-Daily, Fixed-Dose Combination of Aclidinium Bromide and Formoterol Fumarate for the Treatment of COPD
- Ultibro Breezhaler, INN-Indacaterol/Glycopyrronium
- Anoro Ellipta (Umeclidinium Bromide and Vilanterol)
- Trimbow, INN-Beclometasone Dipropionate, Formoterol Fumarate
- Therapeutic Class Overview Β2-Agonists Single Entity Agents
- 207930Orig1s000
- Duaklir Pressair (Aclidinium/Formoterol Fumarate), for the Maintenance Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)
- Pharmacological Characterization of a Novel 5-Hydroxybenzothiazolone
- List of Drugs to Be Avoided by Patients with Congenital Long QT Syndrome
- Comparison Between Formoterol 12 Mg B.I.D. and On-Demand Salbutamol in Moderate Persistent Asthma
- Long-Acting Bronchodilators: Salmeterol, Formoterol, and Arformoterol
- Trimbow, INN-Beclometasone / Formoterol / Glycopyrronium Bromide
- Lydia Normal.Dot
- Updates in Asthma Treatment
- Redalyc.About the Role of Indacaterol in Obstructive Airways Disorder
- Lung Function Improvements Following Inhaled Indacaterol/Glycopyrronium/Mometasone Furoate Are Independent of Dosing Time in Asthma Patients: a Randomised Trial
- BEVESPI AEROSPHERE Safely and Effectively
- Formoterol, a New Long Acting Beta2 Agonist for Inhalation Twice Daily
- Chirality of Β2-Agonists. an Overview of Pharmacological Activity, Stereoselective Analysis, and Synthesis
- Trelegy, INN-Fluticasone Furoate/Umeclidinium Bromide
- A 6-Month Comparison Between Formoterol and Salmeterol in Patients with Reversible Obstructive Airways Disease
- 022383Orig1s000
- Pharmaceutical Compositions Containing Formoterol Pharmazeutische Zusammensetzung Enthaltend Formoterol Compositions Pharmaceuticales Comprenant Formoterol
- Respiratory Beta-Agonist Combination Agents
- Duaklir, INN-Aclidinium and Formoterol
- DUAKLIR® PRESSAIR® (DU-Aakl-Ir PRESS-Air) (Aclidinium Bromide/Formoterol Fumarate) Inhalation Powder
- Occasional Reviews Long Acting Β2 Agonists and Theophylline in Stable
- Product Monograph Duaklir® Genuair®
- Beta-Adrenergic Agonists
- Umeclidinium Bromide/ Vilanterol Drug Assessment Anoro® for COPD Report No Additions to Efficacy, Just to Price @DTB Navarre.Es
- Long-Acting ~2-Adrenoceptor Agonists: a New Perspective in the Treatment of Asthma
- Role of Indacaterol in the Management of Asthma and Chronic Obstructive Pulmonary Disease
- ATC) Codes and Drug Identification Numbers (Dins
- Attachment: Product Information for Beclometasone Dipropionate/ Formoterol Fumarate/ Glycopyrronium Bromide
- Adrenoceptor Agonists in Asthma Management
- Drug Monograph Drug/Drug Class: Anoro™ Ellipta (Umeclidinium
- Effects of Formoterol, Salmeterol Or Oxitropium Bromide on Airway Responses to Salbutamol in COPD
- Medicines Used to Treat COPD
- Phase I/II Trial of Formoterol Fumarate Combined with Megestrol Acetate in Cachectic Patients with Advanced Malignancy
- Long-Acting Beta Agonists in Asthma and COPD October 2013